E Haroon, AW Daguanno… - …, 2018 - pubmed.ncbi.nlm.nih.gov
Background One third of patients with major depressive disorder (MDD) fail to respond to currently available antidepressant medications. Inflammation may contribute to treatment …
E Haroon, AW Daguanno, BJ Woolwine… - …, 2018 - Elsevier
Background One third of patients with major depressive disorder (MDD) fail to respond to currently available antidepressant medications. Inflammation may contribute to treatment …
E Haroon, AW Daguanno, BJ Woolwine… - …, 2018 - cir.nii.ac.jp
Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder | CiNii Research CiNii 国立情報学研究所 学術情報 …
E Haroon, AW Daguanno, BJ Woolwine… - …, 2018 - psycnet.apa.org
Background: One third of patients with major depressive disorder (MDD) fail to respond to currently available antidepressant medications. Inflammation may contribute to treatment …
E Haroon, AW Daguanno, BJ Woolwine… - …, 2018 - europepmc.org
Background One third of patients with major depressive disorder (MDD) fail to respond to currently available antidepressant medications. Inflammation may contribute to treatment …
E Haroon, AW Daguanno, BJ Woolwine… - …, 2018 - infona.pl
One third of patients with major depressive disorder (MDD) fail to respond to currently available antidepressant medications. Inflammation may contribute to treatment non …
E Haroon, AW Daguanno, BJ Woolwine… - …, 2018 - ncbi.nlm.nih.gov
Background: One third of patients with major depressive disorder (MDD) fail to respond to currently available antidepressant medications. Inflammation may contribute to treatment …
E Haroon, AW Daguanno, BJ Woolwine… - …, 2018 - europepmc.org
Background One third of patients with major depressive disorder (MDD) fail to respond to currently available antidepressant medications. Inflammation may contribute to treatment …